AstraZeneca's nerve damage treatment recommended for approval in EU
21st Oct 2024 07:10
(Sharecast News) - Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU.
Read moreHutchmed reports positive results from AstraZeneca lung cancer collaboration
16th Oct 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys', or savolitinib, in treating patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), who had high levels of MET overexpression or amplification and whose disease progressed after treatment with Tagrisso.
Read moreAstraZeneca enters into exclusive license agreement with CSPC
7th Oct 2024 10:16
(Sharecast News) - Drugmaker AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical to advance the development of a pre-clinical novel lipid-lowering therapy.
Read moreAstraZeneca's Tagrisso gets new US lung cancer approval
26th Sep 2024 07:38
(Sharecast News) - AstraZeneca announced on Thursday that 'Tagrisso', or osimertinib, has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, stage three epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease had not progressed after platinum-based chemoradiation therapy (CRT).
Read moreLondon close: Stocks finish higher after slew of PMI data
23rd Sep 2024 15:05
(Sharecast News) - London's stock markets ended Monday on a positive note, as investors pored over a number of economic activity reports from both the UK and international markets.
Read moreAstraZeneca breast cancer drug trial fails to improve overall survival
23rd Sep 2024 07:17
(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival.
Read moreAstraZeneca's inflammatory disease drug Fasenra approved in the US
18th Sep 2024 07:29
(Sharecast News) - AstraZeneca has received the green light for its Fasenra drug in the US, used to treat patients with a rare inflammatory disease.
Read moreLondon close: Stocks finish firmer in subdued trading
13th Sep 2024 16:44
(Sharecast News) - London stocks closed in positive territory on Friday, bolstered by hopes of an interest rate cut in the United States, although the gains were modest as trading remained subdued.
Read moreLondon close: Stocks mixed on latest UK jobs data
10th Sep 2024 14:47
(Sharecast News) - London's stock markets closed with mixed results on Tuesday, as investors weighed the latest UK jobs data showing both a slowdown in pay growth and a decline in the unemployment rate.
Read moreAstraZeneca shares drop on lung cancer trial update
10th Sep 2024 09:54
(Sharecast News) - The share price of AstraZeneca took a big hit on Tuesday after investors reacted to disappointing news from the company's latest lung cancer trials.
Read moreLondon close: Stocks slip on relatively quiet Friday
16th Aug 2024 17:46
(Sharecast News) - London's stock markets closed lower on Friday, weighed down by a stronger pound and mixed investor sentiment following the release of the latest UK retail sales figures.
Read moreAstraZeneca's Imfinzi gets fresh approval in the US
16th Aug 2024 07:15
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) has approved its drug durvalumab, branded Imfinzi, for the treatment of early-stage non-small cell lung cancer (NSCLC) in patients eligible for surgery.
Read moreAstraZeneca prices EUR 1.4bn eurobond offering
30th Jul 2024 11:56
(Sharecast News) - AstraZeneca announced on Tuesday that its wholly owned subsidiary, AstraZeneca Finance, priced a €1.4bn eurobond offering on 29 July.
Read moreLondon close: Stocks finish mixed at start of busy week
29th Jul 2024 15:35
(Sharecast News) - London stocks closed with mixed results on Monday, reflecting a cautious market sentiment ahead of a busy week of earnings reports and crucial policy announcements from major central banks on both sides of the Atlantic.
Read moreAstraZeneca reports positive results from leukaemia drug trial
29th Jul 2024 07:10
(Sharecast News) - AstraZeneca has hailed positive high-level results from a clinical trial of its Calquence treatment for adults with chronic lymphocytic leukaemia (CLL).
Read more